Meridia (sibutramine) / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meridia (sibutramine) / AbbVie
NCT00134199: A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Completed
2b
282
US
CP-945,598, sibutramine
Pfizer
Obesity
 
11/05
NCT00533481: Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Completed
2
497
US
MK0557
Merck Sharp & Dohme LLC
Obesity
12/04
12/04
NCT00330525: Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity

Completed
2
72
US
sibutramine
Mayo Clinic
Obesity, Overweight
03/06
03/06
NCT00402077: A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Completed
2
258
US
pramlintide acetate, Symlin, sibutramine, Meridia, phentermine, Adipex-P, Fastin, Obenix, Oby-Trim, placebo
AstraZeneca
Overweight, Obesity
08/07
08/07
NCT00537420: A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Completed
2
551
US
Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine, Meridia
Nastech Pharmaceutical Company, Inc.
Obesity
07/08
09/08
NCT00993421: A Weight Loss Study in Overweight Men and Women

Terminated
2
343
US
LY377604, Sibutramine, Metoprolol, Placebo sibutramine, Placebo Metoprolol, Placebo LY377604
Eli Lilly and Company
Obesity
06/10
06/10

Download Options